Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Denali Therapeutics Inc
(NQ:
DNLI
)
25.00
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Denali Therapeutics Inc
< Previous
1
2
3
Next >
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021
September 21, 2021
Upgrades According to Compass Point, the prior rating for TriplePoint Venture Growth BDC Corp (NYSE:
Via
Benzinga
President And CEO Of Denali Therapeutics Sold $1.00 Million In Stock
September 03, 2021
Ryan Watts, President and CEO at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
74 Biggest Movers From Yesterday
July 27, 2021
Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares jumped 109.7% to close at $8.87 on Monday after the company announced it entered into a second strategic co-mining agreement with...
Via
Benzinga
Why Denali Therapeutics Stock Is Sinking Today
July 26, 2021
The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug.
Via
The Motley Fool
48 Stocks Moving In Monday's Mid-Day Session
July 26, 2021
Gainers Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The...
Via
Benzinga
Denali Therapeutics Stock Crashes; Why Investors Are Questioning Its Entire Pipeline
July 26, 2021
Denali unveiled promising test results in Hunter syndrome, but DNLI stock tanked Monday on broader pipeline viability questions.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 26, 2021
Gainers Dynatronics (NASDAQ:DYNT) shares moved upwards by 40.31% to $1.81 during Monday's pre-market session. The company's market cap stands at $31.4 million....
Via
Benzinga
Denali's Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome
July 26, 2021
Denali Therapeutics Inc (NASDAQ: DNLI) announced additional interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310) for the central nervous system (CNS)...
Via
Benzinga
Tuesday Talk: Action!
June 15, 2021
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Biotechs Ready To Roar
June 13, 2021
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...
Via
Talk Markets
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
May 18, 2021
Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,...
Via
Benzinga
Biden's Budget May Boost These 3 Biotechs
May 10, 2021
It signals a big push toward curing a neurological disease with a massive market.
Via
The Motley Fool
Exposures
COVID-19
Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End
May 03, 2021
Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.